The increasing interest in potent weight management has led to considerable exploration into groundbreaking treatments. Currently, Retatrutide, a combined -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor stimulator, has exhibited encouraging results in clinical trials, indicating potential for